CN103052397B - 用于预防及治疗非酒精性脂肪肝疾病的腺病毒ad36 e4orf1蛋白 - Google Patents

用于预防及治疗非酒精性脂肪肝疾病的腺病毒ad36 e4orf1蛋白 Download PDF

Info

Publication number
CN103052397B
CN103052397B CN201180033866.7A CN201180033866A CN103052397B CN 103052397 B CN103052397 B CN 103052397B CN 201180033866 A CN201180033866 A CN 201180033866A CN 103052397 B CN103052397 B CN 103052397B
Authority
CN
China
Prior art keywords
e4orf1
albumen
adenovirus
seq
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180033866.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103052397A (zh
Inventor
N·杜源德哈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of CN103052397A publication Critical patent/CN103052397A/zh
Application granted granted Critical
Publication of CN103052397B publication Critical patent/CN103052397B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180033866.7A 2010-07-08 2011-07-08 用于预防及治疗非酒精性脂肪肝疾病的腺病毒ad36 e4orf1蛋白 Expired - Fee Related CN103052397B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36244310P 2010-07-08 2010-07-08
US61/362,443 2010-07-08
PCT/US2011/043338 WO2012006512A1 (en) 2010-07-08 2011-07-08 Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
CN103052397A CN103052397A (zh) 2013-04-17
CN103052397B true CN103052397B (zh) 2017-09-19

Family

ID=44629893

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180033866.7A Expired - Fee Related CN103052397B (zh) 2010-07-08 2011-07-08 用于预防及治疗非酒精性脂肪肝疾病的腺病毒ad36 e4orf1蛋白

Country Status (11)

Country Link
US (2) US8951980B2 (enExample)
EP (1) EP2590665B1 (enExample)
JP (1) JP5965397B2 (enExample)
KR (1) KR101831638B1 (enExample)
CN (1) CN103052397B (enExample)
AU (1) AU2011274537B9 (enExample)
CA (1) CA2803787C (enExample)
ES (1) ES2550962T3 (enExample)
NZ (1) NZ606236A (enExample)
TW (1) TWI531650B (enExample)
WO (1) WO2012006512A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618374T3 (es) 2012-10-17 2017-06-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Composiciones y métodos para mejorar la absorción de glucosa
US9354963B2 (en) * 2014-02-26 2016-05-31 Microsoft Technology Licensing, Llc Service metric analysis from structured logging schema of usage data
WO2015164312A1 (en) 2014-04-23 2015-10-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College SMALL MOLECULE ANALOGS OF E4orf1
GB201910299D0 (en) * 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064836A1 (en) * 2005-11-30 2007-06-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Adenovirus 36 e4 orf 1 gene and protein and their uses
US20070218081A1 (en) * 2005-12-27 2007-09-20 Atkinson Richard L Adipogenic adenoviruses as a biomarker for disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1626280B1 (en) * 2004-08-12 2007-02-14 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
US20060045919A1 (en) 2004-08-27 2006-03-02 Samueli Institute Homeopathic compositions and methods for the treatment of cancer
JP2008105945A (ja) * 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
JP2008273938A (ja) * 2007-03-30 2008-11-13 Shiseido Co Ltd アディポネクチン産生促進剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064836A1 (en) * 2005-11-30 2007-06-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Adenovirus 36 e4 orf 1 gene and protein and their uses
US20070218081A1 (en) * 2005-12-27 2007-09-20 Atkinson Richard L Adipogenic adenoviruses as a biomarker for disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ad36 adipogenic adenovirus in human non-alcoholic fatty liver disease;Trovato Guglielmo M et al.;《Liver International》;20100228;第30卷(第2期);184-190 *
human adenovirus-36 and non-alcoholic fatty liver disease;Atkinson Richard L;《Liver International》;20100228;第30卷(第2期);164-165 *

Also Published As

Publication number Publication date
ES2550962T3 (es) 2015-11-13
AU2011274537B2 (en) 2016-12-15
CN103052397A (zh) 2013-04-17
EP2590665A1 (en) 2013-05-15
CA2803787C (en) 2018-12-04
CA2803787A1 (en) 2012-01-12
HK1185261A1 (en) 2014-02-14
KR20130100262A (ko) 2013-09-10
AU2011274537A1 (en) 2013-02-14
JP5965397B2 (ja) 2016-08-03
EP2590665B1 (en) 2015-09-16
US20170340699A1 (en) 2017-11-30
NZ606236A (en) 2014-09-26
US20120027845A1 (en) 2012-02-02
AU2011274537B9 (en) 2017-02-23
US8951980B2 (en) 2015-02-10
JP2013531681A (ja) 2013-08-08
TWI531650B (zh) 2016-05-01
WO2012006512A1 (en) 2012-01-12
KR101831638B1 (ko) 2018-02-23
TW201217529A (en) 2012-05-01

Similar Documents

Publication Publication Date Title
Wang et al. miR-26a limits muscle wasting and cardiac fibrosis through exosome-mediated microRNA transfer in chronic kidney disease
Krishnapuram et al. Template to improve glycemic control without reducing adiposity or dietary fat
Altomonte et al. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice
Yoshida et al. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt-and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression
Park et al. Lactobacillus rhamnosus GG improves glucose tolerance through alleviating ER stress and suppressing macrophage activation in db/db mice
Yang et al. Regulation of insulin and leptin signaling by muscle suppressor of cytokine signaling 3 (SOCS3)
Dadson et al. Adiponectin action: a combination of endocrine and autocrine/paracrine effects
Galipeau et al. Novel role of the serine protease inhibitor elafin in gluten-related disorders
CN105056208B (zh) Creg蛋白用于预防或治疗心肌梗死的医药用途
CN103052397B (zh) 用于预防及治疗非酒精性脂肪肝疾病的腺病毒ad36 e4orf1蛋白
Piao et al. A novel plasminogen activator inhibitor‐1 inhibitor, TM5441, protects against high‐fat diet‐induced obesity and adipocyte injury in mice
HK1246149A1 (zh) 溶瘤牛痘病毒组合癌症疗法
US20250320265A1 (en) Brown fat-selective adipokines
Tambo et al. The microbial hypothesis: contributions of adenovirus infection and metabolic endotoxaemia to the pathogenesis of obesity
Liu et al. Ghrelin protects the myocardium with hypoxia/reoxygenation treatment through upregulating the expression of growth hormone, growth hormone secretagogue receptor and insulin-like growth factor-1, and promoting the phosphorylation of protein kinase B
WO2018028433A1 (zh) Creg蛋白用于预防或治疗体重超重、肥胖及其相关疾病的医药用途
JPWO2014027608A1 (ja) 褐色脂肪細胞分化誘導剤
Takanashi et al. Role of hormone-sensitive lipase in leptin-promoted fat loss and glucose lowering
HK1185261B (en) Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
Wang et al. Effects of adenovirus‐mediated liver‐selective overexpression of protein tyrosine phosphatase‐1b on insulin sensitivity in vivo
WO2020223674A2 (en) Methods and compositions for regulating adipogenesis
KR20250052370A (ko) 중증 고중성지방혈증용 조성물 및 치료 방법
Cefalu et al. Template to improve glycemic control without
US20120269796A1 (en) Method for Enhancing Pancreatic Beta Cell Proliferation, Increasing Serum Insulin Concentration, Decreasing Blood Glucose Concentration And Treating And/Or Preventing Diabetes
CN119792581A (zh) TrkB基因在制备肝纤维化治疗产品中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170919

Termination date: 20200708

CF01 Termination of patent right due to non-payment of annual fee